| Identification | Back Directory | [Name]
Acriflavine hydrochloride | [CAS]
69235-50-3 | [Synonyms]
Acid acriflavine
Acriflavine Hydrochloride (mixture of 3,6-Diamino-10-methylacridinium Chloride Hydrochloride and 3,6-Diaminoacridine Hydrochloride)> | [Molecular Formula]
C27H28Cl4N6 | [MDL Number]
MFCD00069039 | [MOL File]
69235-50-3.mol | [Molecular Weight]
578.363 |
| Chemical Properties | Back Directory | [Melting point ]
240-247°C | [bulk density]
380kg/m3 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO (Slightly), Methanol (Slightly), Water (Slightly) | [Water Solubility ]
Soluble in water | [form ]
Powder | [color ]
Orange-red to red-brown | [PH]
1.0 (20°C, 10g/L in H2O) | [Merck ]
14,123 | [Stability:]
Hygroscopic, Light Sensitive |
| Safety Data | Back Directory | [RIDADR ]
3077 | [Autoignition Temperature]
>190°C | [HS Code ]
2933.99.8290 | [HazardClass ]
9 | [PackingGroup ]
III |
| Hazard Information | Back Directory | [Uses]
Acriflavine is an topical antiseptic agent and has also been used for the treatment of external fungal infections. Dyes and metabolites. | [in vivo]
Acriflavine (8 mg/kg; intraperitoneal injection; once a day; 13 administrations) hydrochloride inhibits tumor growth and angiogenesis in NOG mice bearing large HSR-GBM1-Luc cell-derived xenografts[3].
Acriflavine (8 mg/kg; intraperitoneal injection; once a day; 15 administrations) hydrochloride inhibits tumor growth in NOG mice bearing small HSR-GBM1-Luc cell-derived xenografts[3].
Acriflavine (8 mg/kg; intraperitoneal injection; once a day; 10 days of administration) hydrochloride reduces the development of chronic myeloid leukemia and the maintenance of leukemia stem cells in C57BL/6J-CD45.1 mice transplanted with BCR/abl-transduced bone marrow cells[5].
Acriflavine (100 mg/kg orally; 5-15 mg/kg intramuscularly; once a day orally, twice a day intramuscularly; 6 days of administration) hydrochloride inhibits the replication of SARS-CoV-2 in the brain and lungs of K18-ACE2 transgenic mice[6]. | Animal Model: | NOG mice (male and female, 6-8-week-old) with HSR-GBM1-Luc cell - derived xenografts (subcutaneous injection of?HSR-GBM1-Luc cells into the left and right flanks)[3]. | | Dosage: | 8 mg/kg | | Administration: | Intraperitoneal injection, once a day, 13 times or 15 times | | Result: | Inhibited tumor growth.
Also reduced tumor microvessel density, indicating inhibition of tumor vascularization. |
| Animal Model: | C57BL/6J-CD45.1 mice (8-10-week-old) with BCR/abl-induced chronic myeloid leukemia (retroviral transduction of BCR/abl into bone marrow cells and transplantation into recipient mice)[5] | | Dosage: | 8 mg/kg | | Administration: | Intraperitoneal injection, once a day, 10 days | | Result: | Reduced splenomegaly, lung infiltrate with myeloid cells, and white blood cell count in peripheral blood.
Decreased the percentage and number of?GFP+/CD34-/LSK cells in bone marrow, indicating a reduction in leukemia stem cells. |
| Animal Model: | K18-ACE2 transgenic mice (female, 8-10-week-old) infected with SARS-CoV-2 (intranasal infection with the virus)[6] | | Dosage: | 100 mg/kg, 5 mg/kg or 15 mg/kg | | Administration: | Oral administration once a day, intramuscular injection twice a day, 6 days | | Result: | Blocked the infection in the brain and significantly reduced the viral load in the lungs. The effect was more pronounced with oral administration. |
| [storage]
Store at -20°C |
|
| Company Name: |
TCI Europe
|
| Tel: |
320-37350700 |
| Website: |
https://www.tcichemicals.com/de/de/index.html |
| Company Name: |
TCI AMERICA
|
| Tel: |
800-4238616 |
| Website: |
https://www.tcichemicals.com/en/us/index.html |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|